Recent developments in government health policy have taken many by surprise. President Trump’s unfounded assertions about Tylenol and its supposed link to autism, as well as the push for quick FDA approval of leucovorin, have highlighted a troubling disregard for scientific evidence in autism treatments.
Additionally, Health and Human Services Secretary Robert F. Kennedy Jr.’s actions at the CDC—such as terminating key scientists and undermining long-established vaccine guidelines—have further raised concerns.
A recent report pointed out that the FDA is running what some critics consider to be pointless safety investigations into mifepristone, the first abortion medication approved 25 years ago. A letter from Kennedy and FDA Commissioner Dr. Marty McCulley stated that there would be an “independent review of the evidence.” Yet, the HHS secretary hinted that decisions surrounding mifepristone might lean more towards political motivations than on scientific grounds, suggesting that “policy changes will end up going through the White House.”
This isn’t the usual approach for the FDA. For over two decades, I have been involved in rigorous, peer-reviewed research aimed at addressing the FDA’s knowledge gaps regarding medical abortion. In fact, during the previous Trump administration, my research into how mifepristone could be distributed via pharmacy or email was given the green light. This research played a role in the FDA’s 2021 decision to relax certain restrictions on the drug.
With a well-documented history of safety established through real-world applications and over 100 peer-reviewed studies, mifepristone has been utilized by more than 7.5 million Americans since its FDA approval in 2000. Its safety track record is actually better than that of penicillin and Viagra.
So, why are our public health leaders reconsidering a drug that has proven to be so reliable? It seems more like a political agenda aimed at misleading the public with falsehoods.
Following the Supreme Court’s Dobbs decision, medication abortion has gained importance as various states impose bans. Currently, around 25 percent of all abortions in the U.S. are performed via telemedicine, allowing patients to consult a clinician remotely and receive medications either at local pharmacies or through home delivery.
Studies indicate that receiving abortion pills by mail after a telemedicine evaluation is just as safe and effective as in-person consultations. Many patients report that telemedicine provides privacy and saves on travel costs, which is a significant advantage.
Rather than impose further limitations on medical abortion, we should heed scientific evidence, which points in a more positive direction. Removing the remaining restrictions on mifepristone could actually enhance our healthcare.
Canadian research shows that after eliminating in-person dispensing requirements and other restrictions on mifepristone, access to abortion improved while complications remained rare.
The announcement about mifepristone from Secretary Kennedy isn’t merely about abortion; it reflects a broader governmental trend of undermining science, putting funding for scientific research at risk.
Cuts to staff and funding at the National Institutes of Health, CDC, and other agencies, along with procrastination or cancellation of research grants under questionable pretenses, could potentially reverse years of advancements and jeopardize our leader’s role in science and innovation. These actions conflict with the President’s Executive Order aimed at restoring scientific integrity.
Public health officials and policymakers argue that the FDA must adhere to scientific principles. Future regulatory decisions should be based on solid evidence. In the case of mifepristone, this means acknowledging the clear scientific consensus regarding its safety.
For over a decade, politicians have incrementally restricted abortion access, often neglecting scientific data about the safety of abortion and its vital place in holistic healthcare. This decline in access has been exacerbated since the Dobbs ruling.
We cannot allow this neglect of scientific integrity to extend to our nation’s primary drug regulatory body. The health of the public is at stake.
